Search
ISTH0036
go.drugbank.com/drugs/DB18606InvestigationalISTH0036 is a synthetic 14-mer phosphorothioate antisense oligonucleotide directed against TGF-beta2 mRNA
Sufentanil
go.drugbank.com/drugs/DB00708ApprovedInvestigationalSufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as Dsuvia, the subli...
Tezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigationalTezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector class. It was developed by Vertex Pharmaceuticals and FDA approved in combination with ivacaftor to manage cystic fibrosis. This drug was ap...
Parathyroid hormone
go.drugbank.com/drugs/DB05829ApprovedInvestigationalPreos is a registered trade mark owned by NPS Pharmaceuticals, Inc. The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA).
Simenepag isopropyl
go.drugbank.com/drugs/DB12977InvestigationalSimenepag isopropyl has been used in trials studying the treatment of Ocular Hypertension and Glaucoma, Open-Angle.
Evodenoson
go.drugbank.com/drugs/DB12295InvestigationalEvodenoson has been used in trials studying the treatment of Open-angle Glaucoma and Ocular Hypertension.
Taprenepag
go.drugbank.com/drugs/DB12623InvestigationalTaprenepag has been used in trials studying the treatment of Ocular Hypertension and Glaucoma, Open-Angle.
Bamosiran
go.drugbank.com/drugs/DB12256InvestigationalBamosiran has been used in trials studying the treatment of Glaucoma, Ocular Hypertension, and Open Angle Glaucoma.
Carbazochrome
go.drugbank.com/drugs/DB09012ApprovedWithdrawnCarbazochrome is a hemostatic agent that promotes clotting, preventing blood loss from open wounds. It is an oxidation product of adrenaline which enhances the microcirculatory tone [A19747].
N4-Hydroxycytidine
go.drugbank.com/drugs/DB15660ExperimentalN4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions. N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage. It has shown antiviral activi...